Latest Regulatory Developments News

333D Limited has responded to ASX queries, clarifying that its Bitcoin Treasury Management Policy approval is not price sensitive, while disclosing a $370,500 Bitcoin acquisition funded partly by R&D tax incentives.

PolyNovo Limited stands to benefit from proposed U.S. Medicare changes that introduce a flat reimbursement rate for outpatient wound care skin substitutes, potentially reshaping the competitive landscape in favour of cost-effective, clinically proven products.

Coast Entertainment Holdings faces a potential regulatory intervention as Queensland's Deputy Premier signals intent to take over assessment of its Dreamworld land development application, citing state economic and environmental interests.

Warriedar Resources has secured a crucial ASX waiver allowing the cancellation of 5 million unlisted options without shareholder approval, smoothing the path for Capricorn Metals’ acquisition scheme.

TerraCom Limited reported a statutory loss of A$33.7 million for FY2025 amid lower coal sales and prices, while progressing its Moorlands Thermal Coal Project in partnership with Wintime Energy Group.

Carbonxt Group Limited reported a 7.1% revenue increase and a significant EBITDA improvement in FY25, while commissioning delays at its Kentucky facility temper near-term optimism.

The Star Entertainment Group reported a statutory net loss of $471.5 million for FY25, impacted by regulatory reforms and remediation costs, while securing a $300 million strategic investment to bolster liquidity.

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Reef Casino Trust and Iris Cairns Property Pty Ltd have agreed to increase the takeover bid price to $3.87 per unit, boosting the total offer value to approximately A$192.7 million. The unanimous board recommendation and major unitholder support underscore the deal’s momentum amid regulatory conditions.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.